Ocular Therapeutix (OCUL) Equity Average (2014 - 2026)

Ocular Therapeutix's Equity Average history runs 13 years deep, the most recent figure standing at $617.9 million for Q1 2026.

• In Q1 2026, Equity Average rose 112.62% year-over-year to $617.9 million; the TTM figure through Mar 2026 stood at $617.9 million (up 112.62% YoY), while the FY2025 annual figure was $484.8 million, up 138.55% from the prior year.
• Equity Average was $617.9 million for Q1 2026 at Ocular Therapeutix, up from $456.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $617.9 million in Q1 2026 to a low of $5.5 million in Q3 2023.
• Historically, Equity Average has averaged $212.4 million across 5 years, with a median of $249.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average slumped 91.21% in 2023, then jumped 6570.16% in 2024.
• A 5-year view of Equity Average shows it stood at $40.8 million in 2022, then grew by 21.29% to $49.5 million in 2023, then surged by 574.22% to $333.7 million in 2024, then surged by 36.74% to $456.3 million in 2025, then surged by 35.43% to $617.9 million in 2026.
• The last three Equity Average figures came in at $617.9 million (Q1 2026), $456.3 million (Q4 2025), and $282.1 million (Q3 2025), per Business Quant data.